Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK. It explores the different strains of MRSA and points out the main ways to control their spread. It is intended to be a reference source for all nurses.
[EX A]: What is MRSA?

[EX Q]: If you wish to become a better reader, here are four important things to remember about reading _ : * Knowing why you are reading or what you are reading to find out will often help you to know whether to read rapidly or slowly. * Some things should be read slowly throughout. Examples are directions for making or doing something, arithmetic problems, science and history books, which are full of important information. You must read such things slowly to remember each important step and understand each important ideas. * Some things should be read rapidly throughout. Examples are simple stories meant for enjoyment, news letters from friends, pieces of news from local, or home-town, papers, telling what is happening to friends and neighbors. * In some of your reading, you must change your speed from fast to slow and slow to fast, as you go along. You will need to read certain pages rapidly and then slow down and do more careful reading when you come to important ideas which must be remembered.
[EX A]: Which should be read slowly according to the passage?

[EX Q]: Nerve growth factor (NGF) is an important mediator of pain and hyperalgesia and has become a target of novel analgesic therapeutics. Tanezumab is a humanized IgG(2) antibody that binds NGF with high affinity and specificity. In a study to assess the toxicity and pharmacokinetic properties of tanezumab in adult, male and female, cynomolgus monkeys following weekly intravenous administration of 1, 10, or 30 mg/kg for up to 26 weeks (followed by an 8-week recovery period), tanezumab was well tolerated with no macroscopic or microscopic effects on those brain, spinal cord, nerve, or ganglia sections evaluated. One fifth of tanezumab-treated monkeys developed an antibody response to tanezumab that prevented maintenance of tanezumab exposure between dosing. In the antibody-negative animals, accumulation of tanezumab was observed; steady state was achieved approximately 8 weeks after the first dose of study drug, and exposure to tanezumab was approximately dose proportional with no observed difference between male and female animals. One monkey died during the study; this monkey had findings suggestive of hypersensitivity reaction. The favorable toxicity and pharmacokinetic profile of tanezumab seen in this study supports its further evaluation for the treatment of pain in clinical practice.
[EX A]:
What is the target of tanezumab?